OTCMKTS:SIGY Sigyn Therapeutics (SIGY) Stock Price, News & Analysis → Jeff Bezos & 48 Members of Congress Are Buying ONE Sector… (From InvestorPlace) (Ad) Free SIGY Stock Alerts $5.25 0.00 (0.00%) (As of 06/7/2024 ET) Add Compare Share Share Today's Range$5.25▼$5.2550-Day Range$5.00▼$6.3452-Week Range$2.08▼$12.80VolumeN/AAverage Volume22 shsMarket Capitalization$6.46 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest Get Sigyn Therapeutics alerts: Email Address Ad Crypto 101 MediaShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About Sigyn Therapeutics Stock (OTCMKTS:SIGY)Sigyn Therapeutics, Inc., a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. In addition, it develops ChemoPrep to enhance the tumor site delivery of chemotherapy; ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis; and ImmunePrep to enhance the potential efficacy of immunotherapeutic antibodies. Sigyn Therapeutics, Inc. was founded in 2019 and is headquartered in San Diego, California.Read More SIGY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SIGY Stock News HeadlinesJune 6 at 7:08 AM | americanbankingnews.comFinancial Analysis: BrainsWay (NASDAQ:BWAY) and Sigyn Therapeutics (OTCMKTS:SIGY)May 15, 2024 | finance.yahoo.comSigyn Therapeutics Reports First Quarter 2024 Financial ResultsMay 7, 2024 | finance.yahoo.comSigyn Therapeutics Discloses Publication of "Sigyn Therapy, an Emerging Candidate to Address Endotoxemia, Sepsis, and Drug-Resistant Viral & Bacterial Infections"March 5, 2024 | finance.yahoo.comSigyn Therapeutics™ to Present at Tomorrow’s Emerging Growth ConferenceMarch 5, 2024 | finance.yahoo.comSigyn Therapeutics to Present at Tomorrow's Emerging Growth ConferenceMarch 5, 2024 | globenewswire.comSigyn Therapeutics™ to Present at Tomorrow's Emerging Growth ConferenceFebruary 21, 2024 | globenewswire.comSigyn Therapeutics™ Announces Filing of 2023 Annual Report on SEC Form 10-KFebruary 3, 2024 | finanznachrichten.deSigyn Therapeutics, Inc.: Sigyn Therapeutics Completes Reverse Stock SplitFebruary 2, 2024 | msn.comSigyn Therapeutics Announces 1-for-40 Reverse Stock SplitFebruary 1, 2024 | finance.yahoo.comSigyn Therapeutics Completes Reverse Stock SplitJanuary 30, 2024 | finanznachrichten.deSigyn Therapeutics, Inc.: Sigyn Therapeutics Announces Reverse Stock SplitJanuary 30, 2024 | finanznachrichten.deSigyn Therapeutics, Inc.: Sigyn Therapeutics Releases Letter to ShareholdersJanuary 30, 2024 | markets.businessinsider.comEQS-News: Sigyn Therapeutics Announces Reverse Stock SplitJanuary 30, 2024 | finance.yahoo.comSigyn Therapeutics Announces Reverse Stock SplitJanuary 4, 2024 | finance.yahoo.comSigyn Therapeutics Releases Letter to ShareholdersDecember 12, 2023 | finanznachrichten.deSigyn Therapeutics, Inc.: Sigyn Therapeutics Announces Appointment of Jerry DeCiccio as Chief Financial OfficerDecember 12, 2023 | msn.comSigyn Therapeutics appoints Jerry DeCiccio as finance chiefDecember 12, 2023 | finance.yahoo.comSigyn Therapeutics Announces Appointment of Jerry DeCiccio as Chief Financial OfficerNovember 15, 2023 | finanznachrichten.deSigyn Therapeutics, Inc.: Sigyn Therapeutics Reports Third Quarter 2023 Financial ResultsNovember 15, 2023 | msn.comSigyn Therapeutics Inc GAAP EPS of -$0.02November 14, 2023 | finance.yahoo.comSigyn Therapeutics Reports Third Quarter 2023 Financial ResultsOctober 4, 2023 | finance.yahoo.comSigyn Therapeutics™ Discloses PCT Patent Submission to Enhance Chemotherapy Delivery and Reduce Cancer Treatment ToxicitySeptember 15, 2023 | finance.yahoo.comSigyn Therapeutics to Present at Today’s Emerging Growth Conference and Tomorrow at the National Investment Bankers Association ConferenceJune 23, 2023 | morningstar.comRelay Therapeutics Inc Ordinary SharesMay 22, 2023 | fool.comBeam Therapeutics (NASDAQ: BEAM)See More Headlines Receive SIGY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sigyn Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today6/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolOTCMKTS:SIGY CUSIPN/A CIK1642159 Webwww.sigyntherapeutics.com Phone(619) 353-0800FaxN/AEmployees5Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,150,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-1,022.38% Debt Debt-to-Equity RatioN/A Current Ratio0.03 Quick Ratio0.02 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($2.80) per share Price / Book-1.88Miscellaneous Outstanding Shares1,230,000Free Float264,000Market Cap$6.46 million OptionableNot Optionable Beta-1.84 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. James A. Joyce Ph.D. (Age 62)Co-founder, Chairman & CEO Inventor Comp: $486.04kMr. Craig P. Roberts (Age 70)Co-founder, CTO & Director Comp: $256.46kMr. Gerald DeCiccio CPAM.B.A., Chief Financial OfficerMs. Charlene R. OwenDirector of OperationsDr. Annette Marleau Ph.D. (Age 49)Chief Scientific Officer Key CompetitorsFemasysNASDAQ:FEMYNeuroOne Medical TechnologiesNASDAQ:NMTCNephrosNASDAQ:NEPHSANUWAVE HealthOTCMKTS:SNWVPolyPidNASDAQ:PYPDView All Competitors SIGY Stock Analysis - Frequently Asked Questions How have SIGY shares performed in 2024? Sigyn Therapeutics' stock was trading at $0.1183 at the beginning of the year. Since then, SIGY shares have increased by 4,339.7% and is now trading at $5.25. View the best growth stocks for 2024 here. How were Sigyn Therapeutics' earnings last quarter? Sigyn Therapeutics, Inc. (OTCMKTS:SIGY) announced its quarterly earnings results on Tuesday, May, 14th. The company reported ($0.62) EPS for the quarter. How do I buy shares of Sigyn Therapeutics? Shares of SIGY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:SIGY) was last updated on 6/9/2024 by MarketBeat.com Staff From Our PartnersCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredMissed NVDA? Buy this AI stock NOWAfter Nvidia's record-breaking earnings surge, Wall Street is now selling the stock at the fastest pace in sev...Chaikin Analytics | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sigyn Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sigyn Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.